|Bid||0.6200 x 900|
|Ask||0.6490 x 1000|
|Day's Range||0.6219 - 0.6484|
|52 Week Range||0.3300 - 1.0200|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
The Campbell, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15 million in the period. In the final minutes of trading on Tuesday, the ...
Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., Aug. 07, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...
CAMPBELL, Calif., Aug. 06, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Suh was President and CEO of Willow Biopharma Inc., ...
CAMPBELL, Calif., July 31, 2018-- VIVUS, Inc. today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August ...
VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension-. CAMPBELL, Calif., July 10, 2018-- VIVUS, Inc., a biopharmaceutical ...
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S. and Canadian rights to PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) from Janssen Pharmaceuticals, Inc. (Janssen) for $135 million. Concurrently, VIVUS completed its previously announced financing agreement with Athyrium Capital Management, L.P. (Athyrium). “The restructuring of a portion of our debt coupled with the acquisition of a cash flow generating asset, PANCREAZE, will move VIVUS towards our goal of becoming an operating profit generating specialty pharmaceutical company. The PANCREAZE transaction fits a well-defined strategy of acquiring assets utilizing VIVUS’ improving operational and financial discipline as a base platform,” said John Amos, Chief Executive Officer at VIVUS.
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.
Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.
Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness; Vivus soared on potential to beat weight-loss drugs with significant adverse effects Bellus ...
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
The Campbell, California-based company said it had a loss of 10 cents per share. The biopharmaceutical company posted revenue of $11.9 million in the period. In the final minutes of trading on Tuesday, ...